CytoDyn to Present Updated Data from Phase 2 CLOVER Study at ESMO Congress 2026
News related to:CytoDyn · 2 min read
VANCOUVER, Washington, Oct. 08, 2026 /CourierPR/ -- CytoDyn, a clinical-stage oncology company, is set to present updated data from its ongoing Phase 2 CLOVER study at the ESMO Congress 2026, taking place from October 23 to 27 in Madrid, Spain. The study, identified by the ClinicalTrials.gov Identifier NCT06699836, evaluates the efficacy of leronlimab in combination with trifluridine and tipiracil (TAS-102) plus bevacizumab in patients with previously treated metastatic colorectal cancer (mCRC).
Leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor, is being explored by CytoDyn for its potential therapeutic benefits in various solid-tumor oncology indications, including colorectal cancer and metastatic triple-negative breast cancer.
The presentation is part of the ESMO Congress 2026, a leading global oncology meeting that brings together clinicians, researchers, patient advocates, journalists, and healthcare industry representatives from around the world. The Congress provides a platform for new scientific data, educational programming, networking opportunities, and innovation across the oncology community.
The CLOVER study is evaluating leronlimab in combination with trifluridine and tipiracil (TAS-102) plus bevacizumab in patients with previously treated mCRC. This combination therapy aims to leverage the unique properties of leronlimab, which targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. The study's findings are expected to contribute significantly to the understanding of CCR5 biology in colorectal cancer and help inform the continued development of leronlimab in combination with established therapies for patients with difficult-to-treat disease.
CytoDyn's commitment to advancing leronlimab as a transformative treatment for patients with difficult-to-treat diseases remains steadfast. The company is dedicated to improving patients' quality of life through therapeutic innovation and is eager to share the latest findings from the CLOVER study at the ESMO Congress 2026. The poster will be available on CytoDyn’s website, providing a detailed overview of the study's results and insights.
The ESMO Congress 2026 is a significant event in the oncology community, attracting a diverse array of participants from around the world. The Congress offers a comprehensive program that includes plenary sessions, satellite symposia, workshops, and poster sessions, all aimed at advancing the field of oncology through cutting-edge research and collaboration.
CytoDyn's presentation at the ESMO Congress 2026 is expected to generate significant interest and discussion among attendees, contributing to the broader understanding of leronlimab's potential in treating metastatic colorectal cancer. The company's ongoing efforts to develop leronlimab as a first-in-class therapeutic agent underscore its commitment to addressing unmet medical needs in oncology.